More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...

The new trial, funded by Pfizer, compared the company’s mRNA shot to Fluzone, one of the most widely used seasonal flu ...

In a large-scale trial, modRNA was significantly better at preventing confirmed flu cases than a typical seasonal flu shot.

Pfizer offers value with a strong dividend, Metsera obesity expansion, PADCEV/Keytruda approval, and an oncology pipeline.

FRIDAY, Nov. 21, 2025 (HealthDay News) — Pfizer’s mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 ...

Pfizer-funded study finds a next-gen mRNA flu shot works better against current strains — but causes more short-term side ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Changes to the ways in which the FDA plans to regulate vaccines represent a threat to effective vaccines and public health, ...

Vaccine experts said the memo was irresponsible and omits key details about how officials arrived at the conclusion.

Multiple companies and organizations have announced early results about their COVID-19 vaccines. Here's what we know about ...

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become ...